Scarica l'app Stockscreener
721.05
2.67%
18.78
Dopo l'orario di chiusura:
718.00
-3.05
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$702.27
Aprire:
$703.33
Volume 24 ore:
738.67K
Relative Volume:
1.07
Capitalizzazione di mercato:
$75.59B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
17.57
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+5.05%
1M Prestazione:
-5.50%
6M Prestazione:
+11.47%
1 anno Prestazione:
+29.10%
Intervallo 1D:
$702.50
$726.16
Intervallo di 1 settimana:
$688.95
$726.16
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
TD Cowen Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $960 - 富途牛牛
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank AB - MarketBeat
Does Regeneron’s Gene Therapy Milestone and Buyback Shift the Bull Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Insider Sell: Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN) - GuruFocus
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MSN
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
REGN Stock Quote Price and Forecast - CNN
Chronic Spontaneous Urticaria Market Size 2026-2033 Industry - openPR.com
Varma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dupixent shows improved esophageal function in EoE trial - Investing.com
Dupixent shows improved esophageal function in EoE trial By Investing.com - Investing.com Canada
Regeneron wins FDA approval for hearing loss therapy - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Horizon Investments LLC - MarketBeat
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 100 Shares of Stock - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLC - MarketBeat
Kornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline Developments - Yahoo Finance
Cash-Rich Companies: One to Watch, Two to Sell in 2026 - IndexBox
Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fifth Third Bancorp Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth - Insider Monkey
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? - The Globe and Mail
Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Weakness - simplywall.st
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00 - MarketBeat
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - BioPharma Dive
Rothschild & Co Redburn Adjusts Regeneron Pharmaceuticals PT to $1,000 From $950 - Moomoo
Wealthfront Advisers LLC Purchases 2,202 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State of New Jersey Common Pension Fund D Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Danske Bank A S Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Presses Amgen for Eylea Antitrust Damages Evidence - Bloomberg Law News
Royal Bank Of Canada Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings - Benzinga
REGN Maintained by Barclays -- Price Target Lowered to $917 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $917.00 Price Target at Barclays - MarketBeat
Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923 - marketscreener.com
Wells Fargo Adjusts Regeneron Pharmaceuticals PT to $800 From $825 - marketscreener.com
Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913 - marketscreener.com
Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00 - MarketBeat
REGN Maintains by Truist Securities -- Price Target Lowered to $796 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $800.00 Price Target at Wells Fargo & Company - MarketBeat
RBC Trims Price Target on Regeneron Pharmaceuticals to $762 From $779, Keeps Sector Perform Rating - marketscreener.com
REGN Maintained by Wells Fargo -- Price Target Lowered to $800 - GuruFocus
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CA - MarketBeat
Regeneron achieves 1st-qtr 2026 double-digit growth - The Pharma Letter
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):